Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa
- Taylor, WR
- Naw, HK
- Maitland, K
- Williams, TN
- Kapulu, M
- D'Alessandro, U
- Berkley, JA
- Bejon, P
- Okebe, J
- Achan, J
- Amambua, AN
- Affara, M
- Nwakanma, D
- van Geertruyden, JP
- Mavoko, M
- Lutumba, P
- Matangila, J
- Brasseur, P
- Piola, P
- Randremanana, R
- Lasry, E
- Fanello, C
- Onyamboko, M
- Schramm, B
- Yah, Z
- Jones, J
- Fairhurst, RM
- Diakite, M
- Malenga, G
- Molyneux, M
- Rwagacondo, C
- Obonyo, C
- Gadisa, E
- Aseffa, A
- Loolpapit, M
- Henry, MC
- Dorsey, G
- John, C
- Sirima, SB
- Barnes, KI
- Kremsner, P
- Day, NP
- White, NJ
- Mukaka, M
Publication date
January 2018
DOI Publisher
BioMed Central ISSN
1741-7015 Journal
1741-7015Abstract
In 2012, the World Health Organization recommended blocking the transmission of Plasmodium falciparum with single low-dose primaquine (SLDPQ, target dose 0.25 mg base/kg body weight), without testing for glucose-6-phosphate dehydrogenase deficiency (G6PDd), when treating patients with uncomplicated falciparum malaria. We sought to develop an age-based SLDPQ regimen that would be suitable for sub-Saharan Africa
Add to ORKG